Quick Links

Randomized trial of Latent TB therapy

Project Information
Description: 
Compares 4 months Rifampin with 9 months INH. In Brazil, Korea, Australia, Benin, Saudi Arabia
Project Date: 
2009-08-02 - 2015-12-31
Type of Project: 
Research
Research Area: 
Health Research
Sub-Research Area: 
Other
Other Sub-Research Area: 
Public Health
Funding Source: 
CIHR

Locations

South Korea
Benin
Saudi Arabia
Australia
Brazil

McGill University Project Leader Information

Project Leader: 

Dick Menzies

Primary Position

Faculty: 
Faculty of Medicine
Institute: 
McGill University Health Centre (MUHC)
Other Institute: 
Montreal Chest Institute
Position/Appointment: 
Professor
Research Interests: 
Tuberculosis - clinical studies of new diagnostic tests, long term outcome, side effects of therapy, and compliance with therapy. Epi studies - of health care workers. Molecular epi studies- effect of BCG on - transmission, transmission to HCW. Building related illnesses - epidemiological studies: of effect of GUV light, effect of microbial contamination and endotoxin.
Selected Publications: 

Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment Completion and Costs (in a Randomized Trial) of 4 Months Rifampin vs 9 Months Isoniazid. American Journal of Respiratory and Critical Medicine 2004

Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. American Journal of Respiratory and Critical Care Medicine 2003; 167: 1472-1477.

Menzies D, Fanning A, Yuan L, FitzGerald JM and the Canadian Collaborative Group in Nosocomial transmission of TB. Hospital ventilation and tuberculin conversion in health care workers. Annals of Internal Medicine 2000; 133: 779-789.

Role: 
Principal Investigator

Non-McGill Partners

Partner: 

Anete Trajman

Country: 
Brazil
University/Organization: 
Gama Filho Universidade